from primary research to a clinical development company · chronic p. aeruginosa infections. • a...
TRANSCRIPT
![Page 1: From Primary Research to a Clinical Development Company · chronic P. aeruginosa infections. • A focus on Quorum Sensing Inhibition. • Development of resistance in patients after](https://reader034.vdocument.in/reader034/viewer/2022052101/603a9a0012c33f78ee4be6ec/html5/thumbnails/1.jpg)
From Primary Research to a Clinical Development Company
MediWales Members’ Showcase
3rd October 2017
Michael Graz
![Page 2: From Primary Research to a Clinical Development Company · chronic P. aeruginosa infections. • A focus on Quorum Sensing Inhibition. • Development of resistance in patients after](https://reader034.vdocument.in/reader034/viewer/2022052101/603a9a0012c33f78ee4be6ec/html5/thumbnails/2.jpg)
Introducing Neem Biotech
Started as a developer of
extraction processes
Now pioneering a
new way to combat
antimicrobial resistance
Healthy and sustainable
livestock industry
Combatting antimicrobial
resistance
Areas of research interest
Liver health, weight
management
![Page 3: From Primary Research to a Clinical Development Company · chronic P. aeruginosa infections. • A focus on Quorum Sensing Inhibition. • Development of resistance in patients after](https://reader034.vdocument.in/reader034/viewer/2022052101/603a9a0012c33f78ee4be6ec/html5/thumbnails/3.jpg)
The Expansion of Neem
• St Mellons Cardiff Site • 1996 • Neem is a spinout of Cardiff
Chemicals
![Page 4: From Primary Research to a Clinical Development Company · chronic P. aeruginosa infections. • A focus on Quorum Sensing Inhibition. • Development of resistance in patients after](https://reader034.vdocument.in/reader034/viewer/2022052101/603a9a0012c33f78ee4be6ec/html5/thumbnails/4.jpg)
From 3 men in a shed 21 years ago...
![Page 5: From Primary Research to a Clinical Development Company · chronic P. aeruginosa infections. • A focus on Quorum Sensing Inhibition. • Development of resistance in patients after](https://reader034.vdocument.in/reader034/viewer/2022052101/603a9a0012c33f78ee4be6ec/html5/thumbnails/5.jpg)
Selection of a New Facility
Abertillery • A desire to remain in south Wales
as Neem has established a strong local network.
• Good Location for existing staff.
• Great building. • Funding opportunities.
![Page 6: From Primary Research to a Clinical Development Company · chronic P. aeruginosa infections. • A focus on Quorum Sensing Inhibition. • Development of resistance in patients after](https://reader034.vdocument.in/reader034/viewer/2022052101/603a9a0012c33f78ee4be6ec/html5/thumbnails/6.jpg)
...To our own place in Abertillery
![Page 7: From Primary Research to a Clinical Development Company · chronic P. aeruginosa infections. • A focus on Quorum Sensing Inhibition. • Development of resistance in patients after](https://reader034.vdocument.in/reader034/viewer/2022052101/603a9a0012c33f78ee4be6ec/html5/thumbnails/7.jpg)
Custom built facilities
![Page 8: From Primary Research to a Clinical Development Company · chronic P. aeruginosa infections. • A focus on Quorum Sensing Inhibition. • Development of resistance in patients after](https://reader034.vdocument.in/reader034/viewer/2022052101/603a9a0012c33f78ee4be6ec/html5/thumbnails/8.jpg)
Analytical Lab 800 sqft
Chemistry and Biochemistry lab 1200 sqft
Class 2 Microbiology lab 800 sqft
R&D at Neem
![Page 9: From Primary Research to a Clinical Development Company · chronic P. aeruginosa infections. • A focus on Quorum Sensing Inhibition. • Development of resistance in patients after](https://reader034.vdocument.in/reader034/viewer/2022052101/603a9a0012c33f78ee4be6ec/html5/thumbnails/9.jpg)
Neem and Plants as Medicine
Of the 12 most important plant-derived medicines brought to the market in the last 30 years, Neem has worked on:
Artemesinin (Artermesia annua) against Malaria. Led to the Nobel prize in Medicine in 2015
Processed raw extracts for a global pharmaceutical firm
Galanthamine (Galanthus caucasius) against Alzheimers. With a strong Welsh connection
Developed an extraction method
Paclitaxel (Taxus brevifolia) for cancer chemotherapy Developed an analysis method
![Page 10: From Primary Research to a Clinical Development Company · chronic P. aeruginosa infections. • A focus on Quorum Sensing Inhibition. • Development of resistance in patients after](https://reader034.vdocument.in/reader034/viewer/2022052101/603a9a0012c33f78ee4be6ec/html5/thumbnails/10.jpg)
Case Study – Cystic Fibrosis
• A chronic and progressive life-threatening autosomal recessive disorder.
• Caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
• Abnormal chloride transportation across cell membranes, leading to mucosal build up in the respiratory, pancreatic, and intestinal epithelia.
• Mucus build up in the lungs is the primary cause of morbidity and mortality in patients with Pseudomonas aeruginosa infection.
• An average life expectancy of <40 years in Europe.
![Page 11: From Primary Research to a Clinical Development Company · chronic P. aeruginosa infections. • A focus on Quorum Sensing Inhibition. • Development of resistance in patients after](https://reader034.vdocument.in/reader034/viewer/2022052101/603a9a0012c33f78ee4be6ec/html5/thumbnails/11.jpg)
Case Study – Cystic Fibrosis
• Organosulpur-based treatment for CF patients suffering with chronic P. aeruginosa infections.
• A focus on Quorum Sensing Inhibition.
• Development of resistance in patients after prolonged and frequent courses of antibiotics.
• Targeting the QS system and the biofilm formation presents a novel mechanism of action for treating P. aeruginosa infection in CF patients.
![Page 12: From Primary Research to a Clinical Development Company · chronic P. aeruginosa infections. • A focus on Quorum Sensing Inhibition. • Development of resistance in patients after](https://reader034.vdocument.in/reader034/viewer/2022052101/603a9a0012c33f78ee4be6ec/html5/thumbnails/12.jpg)
Case Study – Cystic Fibrosis
• NX-AS-401 as a solution
• Preclinical effectiveness to: - improve mucoid P. aeruginosa lung clearance, - Enhanced killing of P. aeruginosa biofilms when combined
with existing antibiotics - Possibility for long term use without drug resistance
• First in human clinical trial scheduled for 2018
![Page 13: From Primary Research to a Clinical Development Company · chronic P. aeruginosa infections. • A focus on Quorum Sensing Inhibition. • Development of resistance in patients after](https://reader034.vdocument.in/reader034/viewer/2022052101/603a9a0012c33f78ee4be6ec/html5/thumbnails/13.jpg)
Neem’s current interest in medicinal chemistry
Plants as food and medicine
Learn from scaffolds found
in nature
Neem’s historical interest in medicinal chemistry
Organosulphur compounds
First-in-man clinical trial
In summary
Wrapping up